Skip to content

    Cohance Life

    COHANCEGood
    Healthcare·28 Oct 2025
    Management Summary

    Cohance Lifesciences used its Q2 FY26 update call to announce a significant organizational restructuring following the resignation of its Managing Director. The company is moving toward a vertical-led structure with three new business CEOs reporting to the Executive Chairman to accelerate its $1 billion revenue target for 2030. While no financial results were disclosed due to a silent period, management highlighted strong momentum in the CDMO pipeline, including a key Phase 3 win from a Japanese client.

    Highlights

    7

    • Management announced a major leadership transition with Managing Director Dr. Prasada Raju stepping down; he will remain for a transition period until the end of the fiscal year.

    • Reiterated long-term strategic vision to reach US$1 billion in revenue by 2030, driven by three core business engines: Pharma CDMO, API Plus, and Specialty Chemicals.

    • Confirmed a significant milestone with a large Japanese customer confirming a Phase 3 order, triggering the capitalization of the SuryaPet facility.

    • The Oligonucleotide unit (Surya) in Nacharam has completed equipment validation and is on track for commissioning in Q4 FY26.

    • Management disclosed that the Nacharam FTF unit's recent OI classification impacts less than 1% of overall EBITDA; remediation is underway with U.S. and Indian consultants.

    • The company is transitioning from a collection of six family-owned businesses into a single integrated global platform with a new brand identity unveiled at CPHI Frankfurt.

    • Management maintained a 'silent period' regarding specific Q2 financial numbers, focusing the call entirely on leadership and operational updates.

    Concerns

    1

    • Leadership Instability

    What Changed3

    vs Q3 FY26

    Guidance items11 → 3 (-8)Risks discussed6 → 3 (-3)Q&A highlights7 → 3 (-4)

    Segment breakdown

    Nacharam FTF Unit
    100% EBITDA Impact
    List

    Guidance & targets

    3
    CategoryTargetPriority
    Revenue
    Total Revenue Vision
    US$1 billion
    		High
    Capacity
    Oligonucleotide Unit Commissioning
    Commissioned
    		High
    Other
    Cash Flow Status
    Cash Positive
    		Medium

    Risks & concerns

    5
    RiskSeverity

    Leadership Instability

    The resignation of MD Dr. Prasada Raju follows the earlier exit of Dr. Sudhir Singh, raising concerns about senior-level attrition. — Analyst acknowledged

    high

    Regulatory Remediation at Nacharam

    The Nacharam FTF unit received an OI classification; while EBITDA impact is low (<1%), it requires U.S. consulting expertise for remediation. — Management acknowledged

    medium

    Short-term Margin Pressure from Talent Buildup

    Hiring new business CEOs and a platform COO while legacy roles transition may cause temporary cost overlaps. — Analyst acknowledged

    low

    Areas of Evasion(2)

    • Specific financial performance due to the silent period.
    • Detailed reasons for the MD's resignation beyond 'personal priorities'.

    Q&A highlights

    3

    “There is no single dependency on Dr. Prasada on any specific client. All these relationships were already transferred as part of normal transition to the business CEOs.”

    Investors were concerned about client retention following the MD's exit; management clarified that the new vertical CEOs already own these relationships.

    asked by Chirag Dagli, DSP Asset Managers

    2 min read5 chapters

    Detailed Narrative

    01

    Strategic Leadership Overhaul

    Cohance is moving away from a traditional MD-led structure to a verticalized model where three business CEOs (Pharma CDMO, API Plus, and Specialty Chemicals) report directly to the Executive Chairman. This change follows the resignation of MD Dr. Prasada Raju, who will assist in the transition until the end of the fiscal year. A new Platform COO role has also been created to oversee operations from Hyderabad, bringing 30 years of experience to strengthen the execution backbone.

    02

    CDMO Pipeline and Milestone Wins

    The company reported significant progress in its CDMO business, completing four major customer orders successfully. A key highlight is the confirmation of a Phase 3 order from a large Japanese customer, which management described as a 'very important milestone.' This order will lead to the capitalization of the SuryaPet facility, reinforcing the company's readiness for commercial-scale execution of Phase 3 products.

    03

    Advanced Therapy Expansion

    Cohance is aggressively expanding into niche modalities like Oligonucleotides and Antibody-Drug Conjugates (ADCs). The Surya oligonucleotide unit in Nacharam has finished equipment validation and is slated for commissioning in Q4 FY26. Additionally, the ADC business is gaining traction through partnerships with NJ Bio in the U.S., and the company recently won a large contract with a major CDMO for ADC payloads.

    04

    Regulatory and Remediation Updates

    Management addressed the recent OI (Official Action Indicated) classification of the Nacharam FTF unit. While they emphasized that this business represents less than 1% of overall EBITDA, they are taking it seriously by appointing a leading U.S. FTA consulting firm alongside an Indian firm to guide the remediation process. They remain proactive in addressing agency observations to ensure compliance.

    05

    M&A and Capital Allocation

    The company maintains an in-house M&A team of two experienced professionals and is actively scouting for 'niche tech' capabilities rather than just capacity. Management's preference is to fund these acquisitions through internal accruals to remain cash positive by the end of the strategy period, though they remain open to partial debt if a large, strategic opportunity arises.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.